The Innovation & Growth Investor Evening will showcase leading innovative and imaginative growth companies bringing them together in one room for one evening only!
Presentations from Directors of leading edge growth companies about their latest plans
Opportunity for you to talk face to face with the companies attending
Networking drinks/canapés - your chance talk to other attendees - private investors, wealth managers,
private client brokers, fund managers and financial institutions
Attendance is FREE, but places are strictly limited, so register now!
Supported by the London Stock Exchange
Date: Tuesday 5th November 2013
Venue: Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR
Registration: 6.00pm
REGISTER FOR INNOVATION & GROWTH EVENING NOW
Presentations: 6.30pm followed by a drinks/canapés reception
Companies presenting include:
Agriterra
Agriterra's strategy is to become one of the largest agri-operators and leading food providers in Africa.
The Company is focused on agricultural investment and sustainable development in Africa, providing high quality produce whilst simultaneously improving the livelihoods of small holder farmers by improving access to markets.
The Company currently has four main divisions: beef ranching; cocoa plantations and trading, maize processing and farming; and palm oil plantations. The Company has built strong brands in its countries of operation, and the Board intends to use these foundations to further grow and diversify its product range in order to gain further market share of the agricultural sector in Africa.
Speakers: Euan Kay, Executive Director
Adrian Simpson, MD of Tropical Farms (a subsidiary of Agriterra)
Angle (AGL)
ANGLE plc is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. ANGLE is listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE has launched a product for the research market and is aiming to secure CE Mark regulatory approval for the clinical market in 2013 with FDA approval in 2014.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:
* Early detection of cancer;
* Personalised cancer treatment;
* Monitoring of cancer patients during treatment; and
* Post-treatment monitoring of cancer patients in remission.
Speaker: Andrew Newland, Chief Executive
Globo (GBO)
Globo plc is engaged in the provision of mobile business services on smartphones, the so-called Bring Your Own Device (BYOD) trend. Globo specialises in software for mobile smartphones that enables companies to run their business operations in a secure environment, and on any device. Globo divested its Greece-based software operations in December 2012, and now provides mobile software products and services in three divisions; services for mobile operators in (32) emerging markets worldwide; services enabling business operations on smartphones, and a software-as-a-service (SaaS) and wireless fidelity (Wi-Fi)-based offering in Greece and the Balkans. Globo acquired Dialect Technologies Inc., in 2012. In February 2013, Globo reached a distribution agreement in North America for its flagship mobile business offering, called GO!Enterprise, with Ingram Micro, the world's largest information technology (IT) services distributor. In August this year Globo became an Advanced Partne within IBM's PartnerWorld programme.
Speaker: Costis Papadrimtrakopoulos, Chief Executive Officer
Tracsis (TRCS)
Tracsis specialises in solving a variety of data capture, reporting and resource optimisation problems along with the provision of a range of associated professional services.
Tracsis' products and services are used to increase efficiency, reduce cost and improve the operational performance and decision making capabilities for clients and customers.
Speaker: John McArthur, Chief Executive Officer